The Cardiovascular Center
Welcome,         Profile    Billing    Logout  
 15 Trials 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Neutel, Joel M
MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Recruiting
3
1328
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Hypertriglyceridemia
07/26
10/26
SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Recruiting
3
405
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Severe Hypertriglyceridemia
07/26
10/26
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
NCT04776629: A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors

Completed
2
77
US
Orticumab, MLDL1278a; BI-204; Anti-oxLDL Antibody, Placebo
Abcentra
Psoriasis, Inflammation, Coronary Artery Disease, Cardiometabolic Syndrome
11/22
11/22
BOLD-HTN, NCT06343298: To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

Recruiting
2
120
US
MANP, Placebo Matched control
E-Star BioTech, LLC, Mayo Clinic, PPD DEVELOPMENT, LP
Difficult to Control Hypertension
09/25
12/25
NCT04828694: Pharmacokinetic and Safety Study of Naltrexone Release From Subcutaneous BICX104 Pellets Compared to Vivitrol Injections

Completed
1
24
US
BICX104, Vivitrol
BioCorRx Inc, National Institute on Drug Abuse (NIDA), The HEAL Initiative (https://heal.nih.gov/)
Opioid-use Disorder
02/23
03/23
NCT05711381: Phase 1 PK Study to Assess Safety, PK, Tolerability of HM15912 in Subjects With Renal Impairment and Normal Renal Function

Completed
1
16
US
HM15912
Hanmi Pharmaceutical Company Limited
Renal Impairment
08/23
08/23
NCT05611957: A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function

Completed
1
29
US
LY3437943
Eli Lilly and Company
Healthy, Renal Insufficiency
09/23
09/23
NCT06592482: A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

Completed
1
30
US
AZD0780
AstraZeneca
Renal Impairment
12/24
12/24
NCT05395481: A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease

Recruiting
1
176
Japan, US
LY3849891, Placebo
Eli Lilly and Company
Non-Alcoholic Fatty Liver Disease
09/26
09/26
NCT06719128: A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants

Not yet recruiting
1
48
US
Olomorasib, LY3537982
Eli Lilly and Company
Hepatic Insufficiency, Healthy
08/25
08/25
LORIS-02, NCT05963594: To Evaluate the Post-Prandial Metabolic Effects of Oligomalt in Adults With T2D and in HAO

Completed
N/A
44
US
Oligomalt, maltodextrin, Glucidex 40
Société des Produits Nestlé (SPN)
Dietary Supplement
03/23
03/23
Chane, Majed
MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Recruiting
3
1328
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Hypertriglyceridemia
07/26
10/26
SHASTA-4, NCT06347016: Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Recruiting
3
300
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Severe Hypertriglyceridemia
07/26
10/26
RENEU-HF, NCT06369298: Study of JK07 in Patients With Chronic Heart Failure

Recruiting
2
282
Canada, US, RoW
JK07, Placebo
Salubris Biotherapeutics Inc
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
12/25
06/26
Valenzuela, Louisito
MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Recruiting
3
1328
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Hypertriglyceridemia
07/26
10/26
SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Recruiting
3
405
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Severe Hypertriglyceridemia
07/26
10/26
Lai, Lara
MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Recruiting
3
1328
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Hypertriglyceridemia
07/26
10/26
SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Recruiting
3
405
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Severe Hypertriglyceridemia
07/26
10/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Neutel, Joel M
MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Recruiting
3
1328
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Hypertriglyceridemia
07/26
10/26
SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Recruiting
3
405
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Severe Hypertriglyceridemia
07/26
10/26
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
NCT04776629: A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors

Completed
2
77
US
Orticumab, MLDL1278a; BI-204; Anti-oxLDL Antibody, Placebo
Abcentra
Psoriasis, Inflammation, Coronary Artery Disease, Cardiometabolic Syndrome
11/22
11/22
BOLD-HTN, NCT06343298: To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

Recruiting
2
120
US
MANP, Placebo Matched control
E-Star BioTech, LLC, Mayo Clinic, PPD DEVELOPMENT, LP
Difficult to Control Hypertension
09/25
12/25
NCT04828694: Pharmacokinetic and Safety Study of Naltrexone Release From Subcutaneous BICX104 Pellets Compared to Vivitrol Injections

Completed
1
24
US
BICX104, Vivitrol
BioCorRx Inc, National Institute on Drug Abuse (NIDA), The HEAL Initiative (https://heal.nih.gov/)
Opioid-use Disorder
02/23
03/23
NCT05711381: Phase 1 PK Study to Assess Safety, PK, Tolerability of HM15912 in Subjects With Renal Impairment and Normal Renal Function

Completed
1
16
US
HM15912
Hanmi Pharmaceutical Company Limited
Renal Impairment
08/23
08/23
NCT05611957: A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function

Completed
1
29
US
LY3437943
Eli Lilly and Company
Healthy, Renal Insufficiency
09/23
09/23
NCT06592482: A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

Completed
1
30
US
AZD0780
AstraZeneca
Renal Impairment
12/24
12/24
NCT05395481: A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease

Recruiting
1
176
Japan, US
LY3849891, Placebo
Eli Lilly and Company
Non-Alcoholic Fatty Liver Disease
09/26
09/26
NCT06719128: A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants

Not yet recruiting
1
48
US
Olomorasib, LY3537982
Eli Lilly and Company
Hepatic Insufficiency, Healthy
08/25
08/25
LORIS-02, NCT05963594: To Evaluate the Post-Prandial Metabolic Effects of Oligomalt in Adults With T2D and in HAO

Completed
N/A
44
US
Oligomalt, maltodextrin, Glucidex 40
Société des Produits Nestlé (SPN)
Dietary Supplement
03/23
03/23
Chane, Majed
MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Recruiting
3
1328
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Hypertriglyceridemia
07/26
10/26
SHASTA-4, NCT06347016: Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Recruiting
3
300
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Severe Hypertriglyceridemia
07/26
10/26
RENEU-HF, NCT06369298: Study of JK07 in Patients With Chronic Heart Failure

Recruiting
2
282
Canada, US, RoW
JK07, Placebo
Salubris Biotherapeutics Inc
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
12/25
06/26
Valenzuela, Louisito
MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Recruiting
3
1328
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Hypertriglyceridemia
07/26
10/26
SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Recruiting
3
405
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Severe Hypertriglyceridemia
07/26
10/26
Lai, Lara
MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Recruiting
3
1328
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Hypertriglyceridemia
07/26
10/26
SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Recruiting
3
405
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Severe Hypertriglyceridemia
07/26
10/26

Download Options